Delgocitinib

• CAT Number: I014767
• CAS Number: 1263774-59-9
• Molecular Formula: C16-H18-N6-O
• Molecular Weight: 310.3592
• Purity: ≥95%
• Synonyms: Delgocitinib; LEO-124249; LEO124249; LEO 124249.
• Target: Stem Cell/Wnt
• IUPAC Name: 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
• InChI: 1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
• InChIKey: LOWWYYZBZNSPDT-ZBEGNZNMSA-N
• SMILES: C[C@H]1CN(C(=O)<wbr>CC#N)<wbr>[C@]12CCN(C2)<wbr>c3ncnc4[nH]ccc34

Delgocitinib (Cat No.: I014767)is a pan-Janus kinase (JAK) inhibitor that targets multiple JAK isoforms (JAK1, JAK2, JAK3, and TYK2), effectively modulating cytokine signaling involved in inflammatory and autoimmune diseases. It is primarily used topically for the treatment of atopic dermatitis, offering anti-inflammatory effects by inhibiting key pathways in immune cell activation. Delgocitinib demonstrates strong efficacy, a favorable safety profile, and minimal systemic absorption. Its broad JAK inhibition makes it a valuable therapeutic option for chronic skin conditions and a promising candidate in dermatological research.

Overview of Clinical Research

Originator: Japan Tobacco
Developer: Japan Tobacco; LEO Pharma
Class: Antiallergics; Antipsoriatics; Pyrimidines; Skin disorder therapies
Mechanism of Action: Janus kinase inhibitors
Orphan Drug Status: No
New Molecular Entity: Yes
Highest Development Phases: Phase III Atopic dermatitis